GRAIL, Inc. (GRAL) saw its stock soar 16.73% in after-hours trading on Thursday, following an optimistic outlook from analysts on the company's prospects in the cancer screening and early detection market.

According to the news article titled "This isn't a 10-stock show right now. Here's where to find opportunities with the S&P 500 at all-time highs," trader Simon Ree highlighted GRAIL as a top holding in the Innovator IB 50 fund (FFTY), an ETF that focuses on companies with strong profit growth, high margins, and high return on equity. The article noted that GRAIL's Apollo Go robotaxi is expected to break even in Wuhan in 2024 and be profitable in 2025 as the company expands its fleet in the city.

Analysts have been bullish on GRAIL's potential in the liquid biopsy market, which aims to detect cancer early through a simple blood test. The company's Galleri multi-cancer early detection test has shown promising results in clinical trials, and its recent partnership with leading healthcare providers has fueled expectations for widespread adoption and revenue growth.